Summary
Normally functioning cell–cell adhesion plays an important role in the maintenance of tissue architecture and cell cohesion. E-cadherin is an important adhesion molecule of epithelial cells. In many types of cancer the expression of E-cadherin is reduced leading to increased risk of disease progression. α-Catenin is one of the intracellular elements of the E-cadherin–catenin complex. The abnormalities in the expression of α-catenin seem to associate with malignant cellular features and disease progression in prostate cancer. To further analyse the significance of α-catenin expression, we studied 215 cases of prostate cancer by immunohistochemistry and the results were related to other known prognostic factors and patient survival during a mean follow-up period of 13 years. α-Catenin expression was down-regulated in 19% of the cases and 3% of the tumours were totally α-catenin-negative. The abnormal α-catenin expression and cytoplasmic signal were significantly linked with high T-category, metastatic disease, high Gleason score, perineural growth, high mitotic rate, high S phase fraction and DNA aneuploidy (P < 0.05 for all). In the survival analysis, reduced α-catenin expression (P = 0.06) and cytoplasmic signal (P = 0.04) were related to unfavourable patient outcome. In the multivariate analysis, including TM-classification and Gleason score, α-catenin expression had independent prognostic value in T1–2 M0 tumors. In the M0 tumours, abnormal α-catenin signal was independently associated with recurrence-free survival as well. The results indicate that down-regulation of α-catenin is related to several malignant cellular features, and it seems to have prognostic significance in the early phases of cancer progression. We suggest that α-catenin expression can provide prognostic information in early prostate cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Behrens, J., Mareel, M. M., Van Roy, F. M. & Birchmeier, W. (1989). Dissecting tumor cell invasion: epithelial cells acquire invasive properties after loss of uvomorulin-mediated cell–cell adhesion. J Cell Biol 108: 2435–2447.
Breen, E., Steele, G. J. & Mercurio, A. M. (1995). Role of the E-cadherin/alpha-catenin complex in modulating cell–cell adhesive properties of invasive colon carcinoma cells. Ann Surg Oncol 2: 375–385.
Crundwell, M. C., Arkell, D. G., Gearty, J. & Phillips, S. M. A. (1997). Genetic alterations in incidentally diagnosed, transitional zone prostate cancer: a seven-year follow-up. J Urol 158: 1568–1575.
Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Löchner, D. & Birchmeier, W. (1991). E-cadherin mediated cell–cell adhesion prevents invasiveness of human carcinoma cells. J Cell Biol 113: 173–185.
Gleason, D. F. (1997). Histological grading and clinical staging of prostate carcinoma. In Urologic Pathology: The Prostate, Pp. 171. Philadelphia: Lea & Febiger
Gumbiner, B. M. & McCrea, P. D. (1993). Catenins as mediators of the cytoplasmic functions of cadherins. J Cell Sci 17: 155–158.
UICC (International Union Against Cancer) (1978). TNM Classification of Malignant Tumors. Geneva: UICC
Isaacs, W. B. (1995). Molecular genetics of prostate cancer. Cancer Surv 25: 357–379.
Morton, R. A., Ewing, C. M., Watkins, J. J. & Isaacs, W. B. (1995). The E-cadherin cell–cell adhesion pathway in urologic malignancies. World J Urol 13: 364–368.
Morton, R. A., Ewing, C. M., Nagafuchi, A., Tsukita, S. & Isaacs, W. B. (1993). Reduction of E-cadherin levels and deletion of alpha-catenin gene in human prostate cancer cells. Cancer Res 53: 3585–3590.
Murant, S. J., Handley, J., Stower, M., Reid, N., Cussenot, O. & Maitland, N. J. (1997). Co-ordinated changes in expression of cell adhesion molecules in prostate cancer. Eur J Cancer 33: 263–271.
Paul, R., Ewing, C. M., Jarrard, D. F. & Isaacs, W. B. (1997). The cadherin cell–cell adhesion pathway in prostate cancer progression. Br J Urol 79: 37–43.
Richmond, P. J. M., Karayiannakis, J. A., Nagafuchi, A., Kaisary, A. V. & Pignatelli, M. (1997). Aberrant E-cadherin and α-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 57: 3189–3193.
Rimm, D. L., Sinard, J. H. & Morrow, J. S. (1995). Reduced α-catenin and E-cadherin expression in breast cancer. Lab Invest 72: 506–512.
Shimazui, T., Brinquier, P. P., van Berkel, H., Ruijter, E., Akaza, H., Debruyne, F. M. J., Oosterwijk, E. & Schalken, J. A. (1997). Decreased expression of alfa-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer 74: 523–528.
Shimazui, T., Schalken, J. A., Giroldi, L. A., Jansen, C. F., Akaza, H., Koisto, K., Debruyne, F. M. & Brinquier, P. P. (1996). Prognostic value of cadherin-associated molecules (α-, β- and γ-catenins and p120cas) in bladder tumors. Cancer Res 56: 4154–4158.
Umbas, R., Isaacs, W. B., Brinquier, P. P., Schaafsma, H. E., Karthaus, H. F. M., Oosterhof, G. O. N., Debruyne, F. M. J. & Schalken, J. A. (1994). Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929–3933.
Umbas, R., Isaacs, W. B., Brinquier, P. P., Xue, Y., Debruyne, F. M. J. & Schalken, J. A. (1997). Relation between aberrant α-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer 74: 374–377.
Van der Wurff, A., Vermeulen, S. J., van der Linden, E. P., Mareel, M. M., Bosman, F. T. & Arends, J. W. (1997). Patterns of α- and β-catenin and E-cadherin expression in colorectal adenomas and carcinomas. J Pathol 182: 325–330.
Vermeulen, S., van Marck, V., van Hoorle, L., van Roy, F., Bracke, M. & Mareel, M. (1996). Regulation of the invasion suppressor function of the cadherin/catenin complex. Pathol Res Pract 192: 694–707.
Vesalainen, S., Lipponen, P., Talja, M. & Syrjänen, K. (1995). Mitotic activity and prognosis in prostatic adenocarcinoma. Prostate 26: 80–86.
Vesalainen, S., Nordling, S., Lipponen, P., Talja, M. & Syrjänen, K. (1994). Progression and survival in prostatic adenocarcinoma: a comparison of clinical stage, Gleason score, S-phase fraction and DNA ploidy. Br J Cancer 70: 309–314.
Vleminckx, K., Vakaet, L., Mareel, M., Fiers, W. & van Roy, F. (1991). Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66: 107–119.
Zsciesche, W., Schonborn, I., Behrens, J., Herrenknecht, K., Hartveit, F., Lilleng, P. & Birchmeier, W. (1977). Expression of E-cadherin and catenins in invasive mammary carcinomas. Anticancer Res 17: 561–567.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Aaltomaa, S., Lipponen, P., Ala-Opas, M. et al. α-Catenin expression has prognostic value in local and locally advanced prostate cancer. Br J Cancer 80, 477–482 (1999). https://doi.org/10.1038/sj.bjc.6690381
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690381
Keywords
This article is cited by
-
Molecular staging of prostate cancer in the year 2007
World Journal of Urology (2007)
-
Prognostic factors in prostate cancer
Diagnostic Pathology (2006)